Journal articleAnn Oncol2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
- Journal
- Ann Oncol
- Published
- 1 June 2017
- Citations
- 74
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsEfficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET NCT01374451↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.